REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 2025
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/
Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire)
The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university students and professionals, and the Teen Edition, reserved for secondary school students.
The competitions will consist of a series of algorithmic programming problems that participants must solve within six hours, using specific input files and adhering to predefined scoring rules. A new feature this year is the integration of cybersecurity challenges based on the Capture the Flag (CTF) model, which will allow participants to unlock additional input files in the categories of Miscellaneous, Crypto, and Web, providing an opportunity to earn extra points and test their skills in cybersecurity.
In the Teen Edition, students will face five progressively difficult problems, with the chance to double their score by solving a bonus CTF. In this edition, the best students will have the opportunity to earn two 50% scholarships for a Bachelor's Program at one of the Albert School campuses (Milan, Geneva, Madrid, Paris, Marseille, and Lyon) of Albert School x Mines Paris PSL; the prestigious Business Data School.
Once again, the learning section of the Reply Challenge platform will be supplemented with "Coding with AI" courses, an area dedicated to learning the potential benefit of utilising artificial intelligence within coding. This section will offer new interactive educational content, including videos, slides, and quizzes, designed to prepare participants for the competition and raise awareness of AI's increasing utilisation in the world of programming.
The problems proposed, which are of a logical-mathematical nature, can be approached with the help of AI tools, which will assist participants in analysing and optimizing solutions. However, artificial intelligence alone will not be enough to overcome these challenges, making the competition an opportunity to explore the potential of this technology as a tool to support the solving of complex problems, while also stimulating participants' analytical skills.
For more information and to register for the competition, visit the website: https://challenges.reply.com.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in designing and implementing solutions based on new communication channels and digital media. Structured as a network of highly specialised companies, Reply supports leading European industrial groups in sectors such as Telco & Media, Industry and Services, Banking and Insurance, and Public Administration, helping define and develop business models enabled by new paradigms such as AI, Cloud Computing, Digital Media, and the Internet of Things. Reply’s services include Consulting, System Integration, and Digital Services. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250131992792/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 14:30:00 CET | Press release
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi
Datopotamab DeruxtecanRecommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 14:00:00 CET | Press release
Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy Datopotamab deruxtecan approved in the U.S. and Japan for same patient population Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 09:00:00 CET | Press release
New $138 million facility at GE HealthCare’s Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end of 2027i Demand for CT and X-Ray contrast media, used to enhance medical imaging procedures globally, is estimated to double in the next ten yearsii Investment will create additional capacity to cater for growing demand, while offering increased flexibility and resiliency for security of supply GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: B
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 08:00:00 CET | Press release
- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY -- Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 - Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President,
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)31.1.2025 07:00:00 CET | Press release
First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabellar lines) beyond 6 months These results reinforce RelabotulinumtoxinA’s 6-month clinical effect and rapid onset from Day 1 demonstrated in the phase III READY clinical trial program1,2 Data also show high and sustained patient satisfaction with treatment outcomes and appearance beyond 6 months1 Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator developed using PEARLTM Technology that is optimized for simple volumetric dosing to increase ease-of-use3,4,5 Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom